Literature DB >> 15187515

Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock.

Mary-Beth Malay1, Jennifer L Ashton, Katherine Dahl, Edward B Savage, Sherryl A Burchell, Robert C Ashton, Robert R Sciacca, Juan A Oliver, Donald W Landry.   

Abstract

OBJECTIVE: To determine whether pressor doses of vasopressin impair organ blood flow in endotoxic shock.
DESIGN: Graded doses of vasopressin or phenylephrine, starting at the clinically recommended doses for pressure support in septic shock, were intravenously infused during endotoxic shock.
SETTING: University hospital surgical research laboratory.
SUBJECTS: Twelve random-bred female Yorkshire pigs.
INTERVENTIONS: We measured mean arterial pressure, cardiac output, heart rate, pulmonary artery occlusion pressure, and carotid, mesenteric, renal, and iliac blood flows.
MEASUREMENTS AND MAIN RESULTS: Low doses of vasopressin (typically used in the clinical management of septic shock) raised arterial pressure by increasing systemic vascular resistance without a significant preferential effect in the circulations measured. However, moderately greater doses of vasopressin had a very heterogeneous vasoconstrictor action; although there was no significant vasoconstriction in the carotid and iliac circulations, mesenteric and renal blood flows decreased markedly. Furthermore, at pressor doses vasopressin improved cerebral perfusion.
CONCLUSIONS: The vasoconstrictor action of exogenous low-dose vasopressin in endotoxic shock does not impair blood flow to any of the vascular beds examined. However, moderately higher doses of vasopressin may induce ischemia in the mesenteric and renal circulations. The data indicate that the safe dose range for exogenous vasopressin in septic shock is narrow and support the current practice of fixed low-dose administration, generally 0.04 units/min and in no case exceeding 0.1 units/min.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187515     DOI: 10.1097/01.ccm.0000128578.37822.f1

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  23 in total

Review 1.  Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity.

Authors:  Emanuel P Rivers; Lauralyn McIntyre; David C Morro; Kandis K Rivers
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

2.  Vasopressin and splanchnic blood flow: vasoconstriction does not equal vasoconstriction in every organ.

Authors:  P Asfar; P Radermacher; B Hauser
Journal:  Intensive Care Med       Date:  2005-11-18       Impact factor: 17.440

3.  Vasopressin as adjunct vasopressor for vasodilatory shock due to non-occlusive mesenteric ischemia.

Authors:  G Luckner; S Jochberger; V D Mayr; H Knotzer; W Pajk; V Wenzel; B Friesenecker; I Lorenz; M W Dünser
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

4.  Hepatorenal syndrome.

Authors:  Bimaljit Singh Sandhu; Arun J Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

5.  Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model.

Authors:  Hans Knotzer; Stephan Maier; Martin W Dünser; Walter R Hasibeder; Hans Hausdorfer; Julia Brandner; Christian Torgersen; Hanno Ulmer; Barbara Friesenecker; Claudia Iannetti; Werner Pajk
Journal:  Intensive Care Med       Date:  2005-11-18       Impact factor: 17.440

6.  Vasopressor hormones in shock-noradrenaline, vasopressin or angiotensin II: which one will make the race?

Authors:  Martin W Dünser; Jens Meier
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

7.  Comparison of the effects of vasopressin and norepinephrine on organ perfusion during septic shock in streptozotocin-induced diabetic rats.

Authors:  Hiroshi Hinohara; Yuji Kadoi; Aya Tokue; Shigeru Saito; Chikara Kawauchi; Akio Mizutani
Journal:  J Anesth       Date:  2010-08       Impact factor: 2.078

8.  Managing drugs and devices in patients with permanent ventricular assist devices.

Authors:  Martin Cadeiras; Manuel von Bayern; Mario C Deng
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

9.  Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial.

Authors:  Florian Simon; Ricardo Giudici; Angelika Scheuerle; Michael Gröger; Pierre Asfar; Josef A Vogt; Ulrich Wachter; Franz Ploner; Michael Georgieff; Peter Möller; Régent Laporte; Peter Radermacher; Enrico Calzia; Balázs Hauser
Journal:  Crit Care       Date:  2009-07-10       Impact factor: 9.097

10.  Vasopressin treatment of verapamil toxicity in the porcine model.

Authors:  J Dave Barry; Dave Durkovich; Lee Cantrell; William Richardson; Tri Tong; Steve Offerman; Richard F Clark; David A Tanen; Saralyn Williams
Journal:  J Med Toxicol       Date:  2005-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.